Pyrazinamide Resistance and pncA Mutation Profiles in Multidrug Resistant Mycobacterium Tuberculosis
- PMID: 36065280
- PMCID: PMC9440668
- DOI: 10.2147/IDR.S368444
Pyrazinamide Resistance and pncA Mutation Profiles in Multidrug Resistant Mycobacterium Tuberculosis
Abstract
Purpose: Pyrazinamide (PZA) is a critical component of standardized chemotherapy for tuberculosis (TB) and is recommended for the treatment of multidrug-resistant (MDR) TB. We aimed to characterize mutations in pncA of M. tuberculosis and evaluate their diagnostic accuracy for PZA susceptibility in China. We also combined genotypic methods with phenotypic susceptibility testing and pyrazinamidase (PZAse) activity to confirm PZA-resistant M. tuberculosis isolates.
Results: An evaluation of 82 MDR M. tuberculosis strains revealed that 28.0% (23/82) were phenotypically resistant to 100 mg/L PZA and 15.9% (13/82) showed resistance to 300 mg/L PZA. Mutations in pncA were detected at 33 unique sites, and the majority were point mutations. No evident mutation hotspots or mutations affecting multiple amino acids were found, but the association between pncA mutations and PZA resistance was significant under 100 and 300 mg/L. The sensitivity of pncA mutation detection for predicting PZA susceptibility was 82.6% (19/23), and the specificity was 61.0% (36/59), based on 100 mg/L PZA, whereas the sensitivity was 84.6% (11/13) and the specificity was 55.1% (38/69), based on 300 mg/L PZA. All mutations identified in the highly PZA-resistant (300 mg/L) strains had an 80% loss relative to PZAse activity. No evident PZAse activity loss was observed in one synonymous mutation strain and the loss exceed 60% in all other strains.
Conclusion: The association between pncA mutation and PZA resistance was significant. Relatively, the molecular method have shown better reliability than the phenotypic method for the detection of PZA resistance. This provides a theoretical basis for the clinical diagnosis of drug-resistant TB.
Keywords: Beijing genotype; DST; MDR; PZA; enzymatic activity; pncA.
© 2022 Shi et al.
Conflict of interest statement
The authors report no conflicts of interest in this work.
Figures
Similar articles
-
Detection of Novel Gene Mutations Associated with Pyrazinamide Resistance in Multidrug-Resistant Mycobacterium tuberculosis Clinical Isolates in Southern China.Infect Drug Resist. 2020 Jan 22;13:217-227. doi: 10.2147/IDR.S230774. eCollection 2020. Infect Drug Resist. 2020. PMID: 32158237 Free PMC article.
-
Phenotypic and molecular characterization of pyrazinamide resistance among multidrug-resistant Mycobacterium tuberculosis isolates in Ningbo, China.BMC Infect Dis. 2021 Jun 25;21(1):605. doi: 10.1186/s12879-021-06306-1. BMC Infect Dis. 2021. PMID: 34171989 Free PMC article.
-
Direct Detection of Pyrazinamide Resistance in Mycobacterium tuberculosis by Use of pncA PCR Sequencing.J Clin Microbiol. 2019 Jul 26;57(8):e00145-19. doi: 10.1128/JCM.00145-19. Print 2019 Aug. J Clin Microbiol. 2019. PMID: 31189582 Free PMC article.
-
[Investigation of pncA, rpsA and panD Gene Mutations Associated with Resistance in Pyrazinamide-Resistant Mycobacterium tuberculosis Isolates and Spoligotyping].Mikrobiyol Bul. 2022 Apr;56(2):191-205. doi: 10.5578/mb.20229801. Mikrobiyol Bul. 2022. PMID: 35477224 Turkish.
-
The paradox of pyrazinamide: an update on the molecular mechanisms of pyrazinamide resistance in Mycobacteria.J Commun Dis. 2006 Mar;38(3):288-98. J Commun Dis. 2006. PMID: 17373362 Review.
Cited by
-
Whole-genome sequencing of clinical isolates from tuberculosis patients in India: real-world data indicates a high proportion of pre-XDR cases.Microbiol Spectr. 2024 May 2;12(5):e0277023. doi: 10.1128/spectrum.02770-23. Epub 2024 Apr 10. Microbiol Spectr. 2024. PMID: 38597637 Free PMC article.
-
The Identification of Novel Mutations in ATP-Dependent Protease ClpC1 Assists in the Molecular Diagnosis of Obscured Pyrazinamide-Resistant Tuberculosis Clinical Isolates.Microorganisms. 2025 Jun 16;13(6):1401. doi: 10.3390/microorganisms13061401. Microorganisms. 2025. PMID: 40572289 Free PMC article.
-
Drug Exposure and Susceptibility of Pyrazinamide Correlate with Treatment Response in Pyrazinamide-Susceptible Patients with Multidrug-Resistant Tuberculosis.Pharmaceutics. 2024 Jan 21;16(1):144. doi: 10.3390/pharmaceutics16010144. Pharmaceutics. 2024. PMID: 38276514 Free PMC article.
References
-
- World Health Organization. Global tuberculosis report 2021. World Health Organization; 2021.
-
- Nahid P, Dorman SE, Alipanah N, et al. Executive Summary: official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: treatment of drug-susceptible tuberculosis. Clin Infect Dis. 2016;63:e147. doi:10.1093/cid/ciw376 - DOI - PMC - PubMed
LinkOut - more resources
Full Text Sources